Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and bio‐optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform

10 Feb 2016

Abstract excerpt

Since the late 1990s, the use of transgenic animal platforms has transformed the discovery of fully human therapeutic monoclonal antibodies. The first approved therapy derived from a transgenic platform--the epidermal growth factor receptor antagonist panitumumab to treat advanced colorectal cancer--was developed using XenoMouse(®) technology. Since its approval in 2006, the science of discovering and developing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26864104
DOI: 10.1111/imr.12409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and bio‐optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platformPMID 26864104Read ↗

Transgenic Mouse Strains as Platforms for the Successful Discovery and Development of Human Therapeutic Monoclonal AntibodiesSemantic proximity Read ↗

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic miceSemantic proximity Read ↗

Strategies for Generating Diverse Antibody Repertoires Using Transgenic Animals Expressing Human AntibodiesSemantic proximity Read ↗

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodiesSemantic proximity Read ↗

Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeuticsSemantic proximity Read ↗

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read ↗

A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studiesSemantic proximity Read ↗

A HUMANIZED FCRN TRANSGENIC MOUSE FOR PRECLINICAL PHARMACOKINETICS STUDIESSemantic proximity Read ↗

Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.Semantic proximity Read ↗

Transgenic goats producing an improved version of cetuximab in milkSemantic proximity Read ↗

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodiesSemantic proximity Read ↗

Antibody discovery ex vivo accelerated by the LacO/LacI regulatory network.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.